[1] CHAUDHRY H M, MAUERMANN M L, VINCENT RAJKUMAR S. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management[J]. Mayo Clin Proc,2017,92(5):838-850.
[2] MAGY L, KABORÉ R, MATHIS S, et al. Heterogeneity of polyneuropathy associated with anti-MAG antibodies[J]. J Immunol Res,2015,2015:450391.
[3] LUNN M P, NOBILE-ORAZIO E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies[J]. Cochrane Database Syst Rev,2016,10(10):CD002827.
[4] KUWAHARA M. Anti-myelin-associated glycoprotein neuropathy[J]. Brain Nerve,2024,76(5):540-546.
[5] LATOV N, SHERMAN W H, NEMNI R, et al. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin[J]. N Engl J Med,1980,303(11):618-621.
[6] MORGANROTH J, KARAM C. Anti-myelin-associated glycoprotein neuropathy: recent developments[J]. Neurol Clin Pract,2025,15(1):e200368.
[7] LEFTER S, HARDIMAN O, RYAN A M. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland[J]. Neurology,2017,88(3):304-313.
[8] PARISI M, DOGLIOTTI I, CLERICO M,et al. Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: clinical, hematological and neurophysiological correlations during 2 years of follow-up[J]. Eur J Neurol,2022,29(12):3611-3622.
[9] AOTSUKA Y, MISAWA S, SUICHI T, et al. Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: a nationwide survey study of 133 patients[J]. Eur J Neurol,2024,31(5):e16249.
[10] 高学敏, 贾鸣男, 钱敏, 等. 抗髓鞘相关糖蛋白抗体阳性 IgM 相关性周围神经病 11 例临床分析[J]. 中华血液学杂志,2019,40(11):901-905.
[11] BOURQUE P R, MASSON-ROY J, WARMAN-CHARDON J,et al. Temporal evolution of nerve conduction study abnormalities in anti-myelin-associated glycoprotein neuropathy[J]. Muscle Nerve,2021,63(3):401-404.
[12] 徐丽玲,宋乐, 常桂林,等. 抗髓鞘相关糖蛋白抗体阳性IgM相关性周围神经病1例报告[J]. 中国临床医学,2023,30(3):557-561.
[13] DONEDDU P E, RUIZ M, BIANCHI E, et al. A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody[J]. Eur J Neurol,2023,30(2):501-510.
[14] DALAKAS M C. Rituximab in anti-MAG neuropathy: more evidence for efficacy and more predictive factors[J]. J Neurol Sci,2017,377:224-226. |
